Union Jack Oil plc (UJO), acknowledges the receipt of a requisition notice dated 7 July 2026 from shareholders who hold 20,650,096 ordinary shares in the Company representing 14.09% of the total voting rights. The Notice requests the Company hold a general meeting to remove its three current directors, being David Bramhill, Joseph O’Farrell and Zac Phillips and to appoint Craig Howie and John Americanos to the Board. The Board will convene the requisite meeting to consider the proposed resolutions in accordance with the statutory timelines and its articles of association.
Comment: It will be interesting to see whether the management here are ready for the fight, have the shares to win, or have already taken action to ensure that they will prevail? As things stand it may be that it would be better if the requisitioners did win the day when it comes. At least then the crackpot / clickbait commentary surrounding the company may finally cease.
Quantum Blockchain Technologies plc (QBT), the AIM-listed investment company focused principally on a research and development programme within blockchain technology, provides a progress update on the development of its Method C AI Oracle software for the ASIC manufacturer’s mining rig and Mining Development Kit. Further to the Company’s announcement of 8 June 2026, QBT is pleased to confirm that the first versions of the AI Oracle have now been successfully generated using the structured operational dataset collected from the ASIC manufacturer’s mining rig. As previously announced, the generation of this dataset represented a key milestone, enabling the Company’s AI learning models to be trained using data produced directly by the ASIC manufacturer’s mining platform. Following the successful generation of the initial AI Oracles, the Company’s research team at the University of Milan has been focusing its efforts on refining the learning process to account for the unique technical characteristics of the new ASIC architecture.
Comment: I was going to say that QBT has done very well for a company that only perhaps five people in the country understand. That said, the share price is in the doldrums, and in the wake of the stellar Delta Gold (AQSE:DGQ) performance, one wonders whether the PR here needs a revamp as far as cutting edge tech.
Zenith Energy Ltd. (ZEN) the listed international energy production and development company, provided shareholders with an update following the successful admission of Reveille Resources PLC (AQSE:REV) to trading on the Aquis Growth Market on 7 July 2026. “The successful admission of Reveille to the Aquis Growth Market marks the successful execution of Zenith’s spin-out strategy. As an energy company, rather than a uranium exploration company, we have always believed that the Novazza and Val Vedello uranium exploration permit applications would achieve their greatest value within a dedicated uranium exploration company with its own management, capital and investor base. Zenith has recovered all of the costs invested in these interests to date while retaining a 25.26% shareholding, making us Reveille’s largest shareholder.”
Comment: It can be seen that ZEN has successfully extracted value for its shareholders in terms of REV, and the hot uranium space it occupies. Indeed, with the Iran ceasefire over, non-fossil fuel sources should be very much back in vogue.
Pulsar Helium Inc. (PLSR), a primary helium company, is pleased to announce the results of its Fundraise, as announced yesterday. Due to strong investor demand, the Company agreed with Canaccord Genuity Limited, who acted as sole bookrunner in connection with the Placing, to increase the gross proceeds of the Placing and Subscription to approximately $25 million (equivalent to approximately £18.7 million / CAD$35.5 million). In addition, the Company has raised gross proceeds of approximately $0.5 million (equivalent to approximately £0.4 million / CAD$0.7 million) from the Retail Offer. The additional proceeds from the Fundraise are intended to be applied towards Topaz Project contingency and corporate working capital.
Comment: It was not exactly a surprise that PLSR has embarked on a large funding move, something which is clearly necessary for it to complete its lofty helium dreams and goals. The issue here is how much the shares can absorb of the funding, and how positive the market’s attitude to helium.
Hamak Strategy Limited (HAMA), a Company combining advanced gold exploration in West Africa with a Digital Asset Treasury Management strategy, announces further high-grade Reverse Circulation (“RC”) intercepts from the Akoko oxide gold project in southwest Ghana. “The remaining drilling at Akoko south is scheduled to complete following the end of the seasonal rains. In the meantime, we now have sufficient drilling results to complete the independent Mineral Resource Estimate for Akoko and I look forward to the results this which will be announced when available.”
Comment: It was suggested here that HAMA will really need to pump up the expectations on the ground in West Africa, and dial down the BTC treasury angle, last year’s false down. It would appear that the company is taking this concept on board.
Sovereign Metals Limited (SVML) confirmed that pursuant to the terms of the Investment Agreement between the Company and Rio Tinto Mining and Exploration Limited (Rio Tinto), Rio Tinto has notified Sovereign that it will not exercise its option to elect to become operator of the Kasiya Rutile-Graphite Project in Malawi. Accordingly, Sovereign will continue as operator and will advance Kasiya directly. Sovereign thanks Rio Tinto for its investment, funding and technical contribution, which have been instrumental in advancing Kasiya to a world-class DFS.
Comment: Perhaps the market was always fearful that the RIO connection was not going to be the big one for SVML, and therefore the shares have glaringly underperformed? It may also be the case that now that SVML is going it alone the overhang of expectation here may finally be lifted.
Fulcrum Metals plc (FMET), a company pioneering the use of innovative cyanide-free technologies to recover precious and critical metals from mine waste and support site regeneration, noted the updated Mineral Resource Estimate (“MRE“) announced by Loyalist Exploration Limited (CSE:PNGC) for the Tully Gold Project in Timmins, Ontario, Canada. The updated MRE exceeds the 200,000 ounce gold resource threshold associated with additional contractual consideration payable to Fulcrum under the terms of the agreement entered into on 2 October 2025 between the Company and Loyalist, subject to the filing of the associated technical report in accordance with the Purchase Agreement.
Comment: It has been stated here on several occasions that FMET has turned the corner permanently on a share price and fundamental basis in a most satisfying way. The cyanide-free company commends even more attention in the wake of the updated MRE announcement today and potentially a new leg higher for the shares from just below the 200 day moving average at 8p.
Physiomics plc (PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announced that it has secured multiple contract awards with a combined estimated value in excess of £200,000. The awards comprise a combination of follow-on engagements within the Company’s Biometrics service line and a new contract within its Modelling & Simulation business. The Biometrics awards include two extensions to existing clinical development engagements: one with a clinical-stage biotechnology company focused on immunology and one with a clinical-stage biotechnology company focused on infectious disease.
Comment: The drip-drip of new business at PYC has been impressive, so impressive that some might question why there was a need for a changing of the guard at the company. However, we are where we are, and few could dispute that under new management the company’s profile has been raised markedly.
EDX Medical Group (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, announces that the Company has been appointed to provide molecular profiling products and services to Astron Health Ltd, a global oncology service providing precision oncology second opinions and molecular profiling interpretation.
Comment: EDX has been great at announcing initiatives such as today’s and equally good at raising cash. The missing part of the puzzle so far has been meaningful revenues / sales et al, something which is required sooner rather than later to get the shares out of the sub 10p zone, and justify the still chunky £34m market cap.
IntelliAM AI (AQSE:INT), the AI-powered predictive maintenance and asset management software company, is pleased to announce a series of new customer purchase orders and contract conversions secured from Q1 commercial activity in the current financial year. INT has received initial purchase orders with an aggregate material value of more than £200,000. These orders comprise a combination of services and software, including deployment of the IntelliAM platform Layer 1 predictive maintenance module, which provides customers with the foundation for further adoption of IntelliAM’s software-led asset performance and reliability offering.
Comment: Interestingly enough despite yesterday’s fundraise announcement at 70p, the shares remain at 80p. Perhaps someone knew today’s orders were on their way? Whatever the case the market would appreciate a tsunami of RNS updates such as today’s in coming months.
Tungsten West (TUN), the mining company focused on restarting production at the Hemerdon tungsten and tin mine in Devon, UK, provided an update on Project commissioning. The Company confirms that it will begin commissioning of its phased production ramp-up later this month. In advance of this, Tungsten West has commenced an enhanced programme of stakeholder engagement, including local community and regulators, to ensure all parties are informed of the timing, scope and staged nature of the commissioning activities.
Comment: Expectations remain high at TUN, especially with the idea that finally Hemerdon can be tamed, something which even experienced geologists fear could be a challenge even with all the money in the world. In the meantime the market continues give the company and its market cap the benefit of the doubt.
Aptamer Group plc (APTA), the developer of next‑generation synthetic binders for the life sciences industry, announces that it has commenced development of Optimer® binders for a potential rapid diagnostic test for the highly infectious Bundibugyo strain of the Ebola virus. Fatality rates for the Bundibugyo strain of Ebola range from approximately 30% to 50%, depending on several factors, including virus strain, patient care quality, and speed of recognition and treatment. Early detection is critical to patient outcomes and outbreak containment.
Comment: We all love to freak out regarding Ebola. Presumably if climate change moves far enough the killer disease could become endemic on the London Underground. But at least APTA is on the zeitgeist as far as such fears, where early detection, as with most things in this space, is key.
Guardian Metal Resources plc (GMET), a strategic exploration company focused on tungsten in Nevada, USA, announced that it has entered into a strategic partnership with the Montana Mining Association to collaborate on a tungsten mining and recovery pilot program supporting domestic defense applications. The Partnership is also being advanced in conjunction with Montana Technological University and the Army Research Laboratory.
Comment: GMET is such a stock market darling that all it needs to do is make a partnership here, or an alliance there and the shares continue their mega bull run. It helps that tungsten is currently one of the most wanted commodities around. That said, those wishing to buy any dip in the stock will be looking to the 200 day moving average zone at 185p.
Contango (CGO) announced that, further to its announcement on 13 February 2026, regarding the Proposed Subscription of £5m at 1.11 pence per share by strategic investors, it has today published and posted the Circular to shareholders. The Circular contains details of the Subscription, Rule 9 Waiver and the notice of general meeting of the Company to be held at Shoosmiths LLP, 1 Bow Churchyard, London EC4M 9DQ at 10 a.m. (UK time) on 29 July 2026.
Comment: The main point to note as far CGO, alongside the company being a serial disappointment, is the way that the chunky fundraise should save the day, and that 1.1p is well above the 0.47p level the shares are currently standing. Everyone loves a premium fundraise.
Victoria PLC (VCP), the international flooring group, announced that it has entered into a binding transaction support agreement with KED Victoria Holdings, LLC and Wood River Capital, LLC and holders representing approximately 2/3rds of its outstanding €166.6 million 3.75% senior secured notes due March 2028. “The Refinancing Transaction eliminates near-term equity dilution risk, reduces senior secured debt and Preferred Shares liabilities by more than £300 million, cuts annual finance costs and PIK dividends by £34 million and extends debt maturities, supported by improved recent trading.”
Comment: It would appear that the market is happy with the latest financing update from VCP. Indeed, the share price has been rebounding sharply in recent months and has exceeded our initial price channel target through 66p. Above 2 year resistance at 77p could drag the shares towards 100p plus.
Avacta Therapeutics (AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director. “I am excited to join the Board of Avacta at this important time for the company. Avacta’s pre|CISION® technology has the potential to change the way that the field thinks about cancer therapy. Upcoming data, including the first clinical results from the Gen Two product AVA6103, could be transformative for Avacta, and I look forward to working with management and my fellow Directors to lead the company on the journey ahead.”
Comment: Beefing up the board is perhaps something which was not urgent as far as AVCT is concerned. However, given that the company remains a stock market darling, the appointment is sure to soothe loyal shareholders after the recent pullback in the stock from the May peak through 90p. The shares are now back near their 200 day moving average at 68p, a charting feature which in recent months has supported the share price.
